We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




Noninvasive Test for Endometriosis Developed

By LabMedica International staff writers
Posted on 07 Dec 2014
Print article
Image: Photomicrograph of endometriosis of the ovary (Photo courtesy of Nephron).
Image: Photomicrograph of endometriosis of the ovary (Photo courtesy of Nephron).
Endometriosis is diagnosed and staged at surgery, resulting in an 11-year latency from symptom onset to diagnosis, underscoring the need for less invasive, less expensive approaches.

Patterns of genetic activity have been identified that can be used to diagnose endometriosis and its severity, a finding that may offer millions of women an alternative to surgery through a simple noninvasive procedure.

Scientists at the University of California San Francisco (CA, USA) identified 148 archived endometrial samples from different menstrual cycle phases from 77 women with endometriosis and pelvic pain and/or infertility; 37 with no endometriosis but with uterine/pelvic pathology (NE.UPP) including symptomatic uterine fibroids, pelvic organ prolapse, and adenomyosis; and 34 with no endometriosis and no uterine/pelvic pathology (NE.NUPP), classified as normal controls.

Whole-tissue samples were processed using rigorous protocols and hybridized to whole-genome microarrays. Total ribonucleic acid (RNA) was purified from specimens, and only high-quality RNA samples were processed for hybridization to Human Genome 133 Plus 2.0 high-density oligonucleotide arrays (Affymetrix; Santa Clara, CA, USA). Menstrual cycle phase was assigned by endometrial histology reviewed by two pathologists, and confirmed by serum estradiol and P4 levels.

The team used machine learning, a computer-based technology, to analyze the gene activity of the endometrium tissue samples. With an accuracy of 90% to 100 %, a grouping system from the samples was developed. Not only could the investigators distinguish between samples from endometriosis patients and the control group but also between the endometriosis patients and those patients with other uterine disorders. They even could denote the difference between endometriosis stages.

This technique also could distinguish endometriosis at different points in the menstrual cycle. As hormone levels changed throughout the cycle, the gene expression patterns in the uterine lining of women with endometriosis were distinct from those who did not have the condition.

Based on this gene expression, a simple test eventually could be performed in the doctor's office to determine endometriosis and stage. In just minutes, a tiny, thin plastic catheter could be inserted through the cervix into the uterus to remove a sample of cells for analysis.

Louis V. DePaolo, PhD, a contributing author of the study said, “Laparoscopy involves general anesthesia and making an incision in the abdomen. These findings indicate that it may be possible to avoid the surgical procedure and diagnose endometriosis from a tissue sample obtained in the office setting without anesthesia.” The study was published on September 22, 2014, in the journal Endocrinology.

Related Links:

University of California San Francisco 
Affymetrix



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The Aperio GT 450 DX has received US FDA 510(k) clearance (Photo courtesy of Leica Biosystems)

Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization

Digital pathology is rapidly becoming a key aspect of modern healthcare, transforming the practice of pathology as laboratories worldwide adopt this advanced technology. Digital pathology systems allow... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.